PURE Bioscience (PURE): Financials
Trailing 12 months ended April 30, 2026
Income statement, cash flow and balance sheet figures for PURE Bioscience (PURE), read directly from the XBRL data the company files with the SEC. Over the trailing twelve months the company reported $2.4M of revenue, up 26.7% year over year. Net loss was $2.2M, or $-0.02 per diluted share. Gross margin stood at 58.8%.
Against the current share price, PURE trades at 3.8 times trailing revenue.
15 fiscal years of history are available, back to 2011.
Frequently asked questions
How much revenue does PURE make?
PURE Bioscience reported $2.4M of revenue over the trailing twelve months, for the period ended April 30, 2026. That is up 26.7% from the same period a year earlier.
Is PURE profitable?
PURE Bioscience was unprofitable over the trailing twelve months, with a net loss of $2.2M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.